Predictors of long-term anamorelin hydrochloride use in patients with cancer cachexia: a single-center real-world retrospective study.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
173 patients with lung, gastric, colorectal, or pancreatic cancer who received anamorelin hydrochloride between May 2021 and May 2025.
I · Intervention 중재 / 시술
anamorelin hydrochloride between May 2021 and May 2025
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Lower mGPS, and better ECOG PS were associated with longer continuation of anamorelin, whereas patients with gastric cancer showed a tendency toward shorter duration. These findings provide guidance for patient selection and tailored supportive care in clinical practice.
[AIM] This retrospective study aimed to identify clinical factors associated with the long-term continuation of anamorelin hydrochloride in real-world clinical practice.
- p-value P = 0.017
- OR 0.333
APA
Kanbayashi Y, Ishikawa T, et al. (2026). Predictors of long-term anamorelin hydrochloride use in patients with cancer cachexia: a single-center real-world retrospective study.. Future oncology (London, England), 22(9), 1095-1101. https://doi.org/10.1080/14796694.2026.2648861
MLA
Kanbayashi Y, et al.. "Predictors of long-term anamorelin hydrochloride use in patients with cancer cachexia: a single-center real-world retrospective study.." Future oncology (London, England), vol. 22, no. 9, 2026, pp. 1095-1101.
PMID
41869701
Abstract
[AIM] This retrospective study aimed to identify clinical factors associated with the long-term continuation of anamorelin hydrochloride in real-world clinical practice.
[PATIENTS AND METHODS] We analyzed 173 patients with lung, gastric, colorectal, or pancreatic cancer who received anamorelin hydrochloride between May 2021 and May 2025. Clinical variables potentially associated with long-term anamorelin continuation were extracted from medical records. Patients were categorized into three groups according to treatment duration: <3 weeks, 3 to <12 weeks, and ≥12 weeks. Univariate and multivariate ordered logistic regression analyses were performed to identify predictors of continued anamorelin use.
[RESULTS] Multivariate analysis identified the Modified Glasgow Prognostic Score (mGPS) (odds ratio [OR] = 0.659, 95% confidence interval [CI] = 0.472- 0.920; = 0.014), gastric cancer (OR =0.333, 95% CI = 0.135- 0.821; P = 0.017), and Eastern Cooperative Oncology Group Performance Status (ECOG PS) (OR =0.616, 95% CI = 0.448- 0.847; = 0.003) as significant predictors.
[CONCLUSION] Lower mGPS, and better ECOG PS were associated with longer continuation of anamorelin, whereas patients with gastric cancer showed a tendency toward shorter duration. These findings provide guidance for patient selection and tailored supportive care in clinical practice.
[PATIENTS AND METHODS] We analyzed 173 patients with lung, gastric, colorectal, or pancreatic cancer who received anamorelin hydrochloride between May 2021 and May 2025. Clinical variables potentially associated with long-term anamorelin continuation were extracted from medical records. Patients were categorized into three groups according to treatment duration: <3 weeks, 3 to <12 weeks, and ≥12 weeks. Univariate and multivariate ordered logistic regression analyses were performed to identify predictors of continued anamorelin use.
[RESULTS] Multivariate analysis identified the Modified Glasgow Prognostic Score (mGPS) (odds ratio [OR] = 0.659, 95% confidence interval [CI] = 0.472- 0.920; = 0.014), gastric cancer (OR =0.333, 95% CI = 0.135- 0.821; P = 0.017), and Eastern Cooperative Oncology Group Performance Status (ECOG PS) (OR =0.616, 95% CI = 0.448- 0.847; = 0.003) as significant predictors.
[CONCLUSION] Lower mGPS, and better ECOG PS were associated with longer continuation of anamorelin, whereas patients with gastric cancer showed a tendency toward shorter duration. These findings provide guidance for patient selection and tailored supportive care in clinical practice.